Study: U.S. Chemo Regimen for Ewing Sarcoma Should Be International Standard Europe and other countries have already followed suit Nov 01, 2022
FDA Broadens Options for Relapsed/Refractory Multiple Myeloma With Teclistamab Bispecific antibody achieved durable responses in a majority of heavily pretreated patients Oct 25, 2022
Transplant With Orca-T Reduced GVHD in Hematologic Malignancies Risk of relapse was also lower in the group who received the cell therapy Oct 03, 2022
ADC Offers Promising Results in Relapsed or Refractory Hodgkin Lymphoma Good response rate with camidanlumab tesirine, although a lot of patients experienced AEs Oct 02, 2022
Anti-BCMA-Based Regimen Impresses in Relapsed/Refractory Myeloma Belamaf plus lenalidomide-dexamethasone achieved encouraging responses Sep 30, 2022
Response-Based Ponatinib Dose Reduction a Win-Win in Chronic-Phase CML? Strategy applied in OPTIC trial may mitigate adverse events without sacrificing benefit Sep 29, 2022
Magrolimab-Azacitidine Shows Promise in Untreated High-Risk MDS About a third of patients, including those with TP53 mutations, achieved complete remission Sep 29, 2022
'Unparalleled Times' in Hematology, but Workforce Issues Persist "This is the most exciting time ever" to be a hematologist, says ASH President Jane Winter, MD Sep 26, 2022 video
What's on Tap at the Society of Hematologic Oncology's 10th Annual Meeting Emphasis on novel biological approaches in treating patients with hematologic malignancies Sep 26, 2022
How a Dedicated Bone Marrow Biopsy Clinic Eased Wait Times VA center in Cleveland got program up and running in about a month Sep 19, 2022
CAR-T Therapy Effective in Youngest Kids With ALL Analysis shows safety and outcomes equivalent to those reported in older children Sep 08, 2022
Jane Fonda's Non-Hodgkin Lymphoma The award-winning actress opened up about her latest health news Sep 06, 2022
Bispecific Antibody Active in Heavily Treated Multiple Myeloma Responses in 60% of patients who had received a median of five prior lines of therapy Aug 30, 2022
Low-Dose Hypomethylating Agents in Lower-Risk MDS Yield Promising Outcomes Overall response rates were 67% with decitabine, 48% with azacitidine Aug 22, 2022
PK Modulator Shows Promise in Thalassemia In small study, mitapivat increased hemoglobin in 80% of non-transfusion-dependent patients Aug 17, 2022
Mandy Moore's Immune Thrombocytopenic Purpura What does it mean for the pregnant pop singer/actress? Aug 10, 2022
Experts Warn of Physical, Mental Health Effects of Extreme Heat Children, people with sickle cell disease, and outdoor workers are particularly at risk Aug 05, 2022
Pneumococcal Vax Slashed Deadly Sickle-Cell Complication in Kids Cumulative ACS reduction of 41% since implementation of 13-valent vaccine, French study finds Aug 02, 2022
'Rogue' Online Pharmacies Are Dispensing Cancer Drugs Shady sites with little oversight are selling imatinib for much less than U.S. retail price Jul 29, 2022
Breast Implant-Related Lymphoma More Common Than Reported Contemporary data suggest at least a twofold higher case rate as compared with FDA estimates Jul 21, 2022
Second-Line CAR-T Impresses in Transplant-Ineligible Large B-Cell Lymphoma More than half of patients achieved complete responses with lisocabtagene maraleucel Jul 18, 2022
Blood Viscosity Enters the Equation in COVID Mortality Its association with death may be unrelated to inflammation Jul 18, 2022
Bone Marrow Biopsy Value Limited in Follicular Lymphoma Response Assessment Information useful in fewer than 1% of patients with untreated disease Jul 10, 2022
Zanubrutinib Wins in First-Line CLL for Older Patients The BTK inhibitor proves superior to bendamustine-rituximab in phase III trial Jul 08, 2022
FDA Warns of Increased Mortality Risk With Duvelisib Drug approved for adults with CLL/SLL Jul 01, 2022
Kidney Failure May Drive COVID Deaths in People With Sickle Cell Trait COVID-19 severity strongly linked with sickle cell anemia as well Jun 27, 2022
Brentuximab Vedotin Boosts Survival in Untreated Hodgkin Lymphoma ECHELON-1 analysis showed 41% mortality risk reduction versus standard treatment Jun 21, 2022
Studies Reinforce Prognostic Role for Circulating Tumor Cells in Myeloma At higher levels, different cutoffs show at least a doubling of PFS, OS hazard ratios Jun 13, 2022
FDA Panel Backs Gene Tx for Degenerative Brain Disorder in Kids Advisers unanimously recommend approval for pediatric ALD patients without HLA-matched donors Jun 10, 2022
Myeloma Trial Supports 'Personalized Approach' to Upfront Transplant DETERMINATION confirms benefit in triple-therapy setting, but suggests timing can be tailored Jun 06, 2022
Third-Line BTK Inhibitor Combo Doubles PFS in Follicular Lymphoma Significantly more responses, CRs with zanubrutinib-obinutuzumab versus anti-CD20 drug alone Jun 05, 2022
Brentuximab Vedotin-Chemo Boosts EFS in High-Risk Pediatric Hodgkin Lymphoma Combo regimen offers "a new standard for front-line therapy," researcher says Jun 04, 2022
Add-On Ibrutinib Boosts PFS in Untreated, Older Mantle-Cell Lymphoma Patients BTK inhibitor plus chemoimmunotherapy increased progression-free survival by over 2 years Jun 03, 2022
FDA Pulls Lymphoma Approvals for PI3K Inhibitor Umbralisib Worse overall survival observed despite improvements in progression-free survival Jun 01, 2022
Unprecedented PFS Improvement in Relapsed Multiple Myeloma Three-year median with addition of isatuximab to proteasome inhibitor backbone May 26, 2022
Elotuzumab Combination Disappoints in Newly Diagnosed Myeloma Study failed to replicate positive results seen in relapsed/refractory setting May 11, 2022
Corticosteroids Linked to Pain Events in Patients With Sickle Cell Disease Hospitalization risk for vaso-occlusive episodes four times higher after exposure May 02, 2022
Promising Data for Allo-Transplant After CAR T-Cell Failure in LBCL Durable responses with no unexpected or prolonged safety issues Apr 27, 2022
Eprenetapopt-Based Combo Impresses in TP53-Mutant AML/MDS 1-year relapse-free survival rate of 60% with maintenance therapy after transplant Apr 25, 2022
BTK Inhibitor Shows Potential in Immune Thrombocytopenia Across doses, 40% of heavily pretreated patients responded to oral rilzabrutinib Apr 13, 2022
